Literature DB >> 14567468

Oral tryptophan challenge studies in cirrhotic patients: no evidence of neuropsychiatric changes.

Andrew Douglass1, Hanan Al Mardini, Christopher O Record.   

Abstract

Hepatic encephalopathy is a frequent complication of cirrhosis. Abnormalities of 5-hydroxytryptamine (5-HT) and its metabolites are recognized and may contribute to its pathogenesis. We therefore studied the effect of an oral tryptophan load (6-18 g) upon psychometric test scores and analyzed EEG's in alcoholic cirrhotic patients. Eight patients had had previous encephalopathic episodes related to variceal bleeds and one patient was awaiting a liver transplant. Five out of the 10 patients had at least one abnormal baseline psychometric test. Following tryptophan challenge there were no changes in blood ammonia but plasma tryptophan levels were elevated approximately 10-fold (p < 0.01 x 10(-7)). Nevertheless, there were no statistically significant changes in psychometric testing or analyzed EEG frequency distribution. All patients reported nausea or vomiting while one patient developed a short-lived serotonin like syndrome. We conclude that in this group of patients, an oral tryptophan load does not induce or worsen subclinical hepatic encephalopathy. If the high blood levels of tryptophan seen in these studies are able to influence cerebral neurotransmitter synthesis, the results do not support a primary role for abnormalities of 5-HT neurotransmission in hepatic encephalopathy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14567468     DOI: 10.1023/a:1025577614928

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  16 in total

Review 1.  Neuropsychological characterization of hepatic encephalopathy.

Authors:  K Weissenborn; J C Ennen; H Schomerus; N Rückert; H Hecker
Journal:  J Hepatol       Date:  2001-05       Impact factor: 25.083

2.  Relationships between tryptophan in serum and CSF, and 5-hydroxyindoleacetic acid in CSF of man: effect of cirrhosis of liver and probenecid administration.

Authors:  S N Young; S Lal; T L Sourkes; F Feldmuller; A Aronoff; J B Martin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-04       Impact factor: 10.154

3.  Amino acid challenge in patients with cirrhosis: a model for the assessment of treatments for hepatic encephalopathy.

Authors:  A Douglass; H Al Mardini; C Record
Journal:  J Hepatol       Date:  2001-05       Impact factor: 25.083

4.  Neuropsychological deficits and morphological MRI brain scan abnormalities in apparently healthy non-encephalopathic patients with cirrhosis. A controlled study.

Authors:  J W Moore; A A Dunk; J R Crawford; H Deans; J A Besson; G De Lacey; T S Sinclair; N A Mowat; P W Brunt
Journal:  J Hepatol       Date:  1989-11       Impact factor: 25.083

5.  Tryptophan metabolism in liver disease.

Authors:  C Hirayama
Journal:  Clin Chim Acta       Date:  1971-04       Impact factor: 3.786

6.  Dynamic and kinetic effects of chronic citalopram treatment in experimental hepatic encephalopathy.

Authors:  G Apelqvist; C Wikell; B Carlsson; S Hjorth; P B Bergqvist; J Ahlner; F Bengtsson
Journal:  Clin Neuropharmacol       Date:  2000 Nov-Dec       Impact factor: 1.592

7.  Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial.

Authors:  C J Rees; K Oppong; H Al Mardini; M Hudson; C O Record
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

8.  Brain indoles in human hepatic encephalopathy.

Authors:  H al Mardini; E J Harrison; P G Ince; K Bartlett; C O Record
Journal:  Hepatology       Date:  1993-06       Impact factor: 17.425

9.  Subclinical hepatic encephalopathy impairs daily functioning.

Authors:  M Groeneweg; J C Quero; I De Bruijn; I J Hartmann; M L Essink-bot; W C Hop; S W Schalm
Journal:  Hepatology       Date:  1998-07       Impact factor: 17.425

10.  Increase in the content of quinolinic acid in cerebrospinal fluid and frontal cortex of patients with hepatic failure.

Authors:  F Moroni; G Lombardi; V Carlà; S Lal; P Etienne; N P Nair
Journal:  J Neurochem       Date:  1986-12       Impact factor: 5.372

View more
  3 in total

1.  Amino acid challenge in patients with cirrhosis and control subjects: ammonia, plasma amino acid and EEG changes.

Authors:  Hanan Al Mardini; Andrew Douglass; Christopher Record
Journal:  Metab Brain Dis       Date:  2006-05-04       Impact factor: 3.584

Review 2.  Pathogenesis of hepatic encephalopathy: lessons from nitrogen challenges in man.

Authors:  Hanan Mardini; Christopher Record
Journal:  Metab Brain Dis       Date:  2012-11-23       Impact factor: 3.584

3.  Lowering blood ammonia prevents hepatocyte injury and apoptosis.

Authors:  Guanmin Gao; Zujiang Yu; Jingya Yan; Jingjing Li; Shen Shen; Bin Jia; Kelei Guan; Xiaojuan Gao; Quancheng Kan
Journal:  Int J Clin Exp Med       Date:  2015-08-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.